Earnings call briefSecond-quarter 2026
Amgen says it now expects 2026 other revenue of approximately $1.9 billion
Amgen also said a $100 million upfront business development payment will raise its third-quarter non-GAAP R&D expense.
GetSignal Amgen AMGN
On its second-quarter call, Amgen said it now expects 2026 other revenue of approximately $1.9 billion. It also expects full-year non-GAAP R&D expense to grow high single digits year-over-year, which includes 9 ongoing global Phase III trials for MariTide.
Amgen now anticipates non-GAAP other income and expense of $2.1 billion to $2.2 billion of expense in 2026.
Quotes from the call
“For the full year, we now expect other revenue to be approximately $1.9 billion.”
Key facts from the call
- Expected 2026 other revenue
- approximately $1.9 billion
- Expected 2026 non-GAAP other income and expense
- $2.1 billion to $2.2 billion of expense
- 2026 share repurchases outlook
- not to exceed $3 billion
Source: Amgen's second-quarter 2026 earnings call, August 4, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
